Nicaraven for the treatment of cerebral vasospasm in subarachnoid haemorrhage

Bibliography

• ASANO T, MATSUI T: Antioxidant therapy against cerebral vasospasm following aneurysmal subarach-noid hemorrhage. Cell Mol. Neurobiol. (1999) 19:31–44.
   PubMed Web of Science ®Google Scholar
• ••Most recent review of the scientific basis of anti-oxidanttherapy for cerebral vasospasm.
   Google Scholar
• KUROKI M, KANAMARU K, SUZUKI H et al: Effect of vasospasm on heme oxygenases in a rat model of subarachnoid hemorrhage. Stroke (1998) 29:683–689.
   PubMed Web of Science ®Google Scholar
• JAIN KK: Neuroprotection in cerebrovascular disease. Exp. Opin. Invest. Drugs (2000) (In press).
   Google Scholar
• ••Strategies for neuroprotection in stroke. Relevant tosecondary indications for the use of nicaraven.
   Google Scholar
• FEIGIN VL, RINKEL GJE, ALGRA A et al: Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage. Neurology (1998) 55:876–883.
   Google Scholar
• JAIN KK: Stroke. D&MD/International Business Communications, Southborough, Massachusetts, USA (1998a).
   Google Scholar
• ••A thorough review of stroke with detailed description ofstrategies for neuroprotection.
   Google Scholar
• YANO K, KURODA T, TANABE Y et al.: Preventivetherapy against delayed cerebral ischaemia after aneurysmal subarachnoid haemorrhage: trials of thromboxane A2 synthetase inhibitor and hyperdy-namic therapy. Acta Neurochir. Wien (1993) 125(1-4):15–19.
   PubMedGoogle Scholar
• TAKEUCHI H, TANABE M, OKAMOTO H eta].: Effects ofthromboxane synthetase inhibitor (RS-5186) on experimentally-induced cerebral vasospasm. Neurol. Res. (1999) 21:513–516
   Google Scholar
• TOSHIMA Y, SATOH S, IKEGAKI I et al.: Thromboxane A2synthetase inhibitor failed to ameliorate the arterial narrowing during the chronic phase of cerebral vasospasm. Life Sci. (1997) 61(14)1371–1377.
   Google Scholar
• YANAMOTO H, KIKUCHI H, SATO M, SHIMIZU Y,YONEDA S, OKAMOTO S: Therapeutic trials of cerebral vasospasm with the serine protease inhibitor, FUT-175, administered in the acute stage after subarachnoid hemorrhage. Neurosurgery (1992) 30:358–363.
   PubMed Web of Science ®Google Scholar
• KAMINOGO M, YONEKURA M, ONIZUKA M et al.: Combination of serine protease inhibitor FUT-175 and thromboxane synthetase inhibitor OKY-046 decreases cerebral vasospasm in patients with subarachnoid hemorrhage. Neurol. Med. Chir. (Tokyo) (1998) 38:704–709.
   PubMed Web of Science ®Google Scholar
• LANZINO G, KASSELL NF, DORSCH NW et al.: Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part I. A cooperative study in Europe, Australia, New Zealand and South Africa. J. Neurosurg. (1999) 90:1011–1017.
   Google Scholar
• LANZINO G, KASSELL NF: Double-blind, randomized,vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part II. A cooperative study in North America. J. Neurosurg. (1999) 90:1018–1024.
   Google Scholar
• KAMII H, KATO I, KINOUCHI H et al.: Amelioration ofvasospasm after subarachnoid hemorrhage in transgenic mice overexpressing CuZn-superoxide dismutase. Stroke (1999) 30:867–872.
   PubMed Web of Science ®Google Scholar
• SHISHIDO T, SUZUKI R, QIAN L et al.: The role ofsuperoxide anions in the pathogenesis of cerebral vasospasm. Stroke (1994) 25:864–868.
   PubMed Web of Science ®Google Scholar
• TOYODA T, KWAN AL, BAVBEK M et al.: Enhanced endogenous antioxidant activity and inhibition of vasospasm in rabbits by pretreatment with a non-toxic endotoxin analog, monophosphoryl A. J. Neurosurgery (1998) 88:1082–1087.
   PubMed Web of Science ®Google Scholar
• THOMAS JE, NEMIROWSKY A, ZELMAN V, GIANNOTTASL: Rapid reversal of endothelin-l-induced cerebral vasoconstriction by intrathecal administration of nitric oxide donors. Neurosurgery (1997) 40:1245–1249.
   PubMed Web of Science ®Google Scholar
• THOMAS JE, ROSENWASSER RH, ARMONDA RA et al:Safety of intrathecal sodium nitroprusside for the treatment and prevention of refractory cerebral vasospasm and ischemia in humans. Stroke (1999) 30:1409–1416.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI T, SANO K, TAKAKURA K et al: Ebselen inacute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke (1998) 29:12–17.
   PubMed Web of Science ®Google Scholar
• WATANABE T, NISHIYAMA M, HORI T et al: Ebselen(DR3305) ameliorates delayed cerebral vasospasm in a canine two-hemorrhage model. Neurol. Res. (1997) 19:563–565.
   PubMed Web of Science ®Google Scholar
• SAITO I, ASANO T, SANO K eta].: Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage. Neurosurgery (1998) 42:269–278.
   Google Scholar
• HARADA T, MAYBERG MR: Inhibition of delayed arterial narrowing by iron-chelating agent deferoxamine. J. Neurosurg. (1992) 77:763–767.
   PubMed Web of Science ®Google Scholar
• HORKY LL, PLUTA RM, BOOCK RJ, OLDFIELD EH: Role of ferrous iron chelator 2,2'-dipyridyl in preventing delayed vasospasm in a primate model of subarach-noid hemorrhage. J. Neurosurg. (1998) 88:298–303.
   PubMed Web of Science ®Google Scholar
• JAIN KK: Textbook of Gene Therapy. Hogrefe & Huber, Gottingen-Seattle, (1998b).
   Google Scholar
• HALLIWELL B: Antioxidants: the basics - what they are and how to evaluate them. Adv. Pharmacol. (1997) 38:3–17.
   PubMedGoogle Scholar
• MARKESBERY WR: Oxidative stress hypothesis inAlzheimer's disease. Free Radic. Biol. Med. (1997) 23:134–147.
   PubMed Web of Science ®Google Scholar
• DARLEY USMAR VM, WISEMAN H, HALLIWELL B: Nitricoxide and oxygen radicals: a question of balance. FEBS Lett. (1995) 369:131–135.
   PubMed Web of Science ®Google Scholar
• TOYODA T, KASSELL NF, LEE KS et al.: Attenuation of ischemia-reperfusion injury in the rat neocortex by the hydroxyl radical scavenger nicaraven. Neurosur-gery (1997) 40:372–378.
   PubMed Web of Science ®Google Scholar
• ••Excellent experimental study.
   Google Scholar
• MASANA Y, YOSHIMINE T, FUJITA T et al.: Reaction of microglial cells and macrophages after cortical incision in rats: effect of a synthesized free radical scavenger, (+/-)-N,N'-propylenedinicotinamide (AVS). Neurosci. Res. (1995) 23:217–221.
   PubMed Web of Science ®Google Scholar
• KU K, KIN S, HASHIMOTO M et al: The role of a hydroxyl radical scavenger (nicaraven) in recovery of cardiac function following preservation and reperfusion. Transplantation (1996) 62:1090–1095.
   PubMed Web of Science ®Google Scholar
• KAMADA K: Sequential observations of brain edema with proton magnetic resonance imaging and spectroscopy. Hokkaido Igaku Zasshi (1996) 71:105–122.
   PubMedGoogle Scholar
• KAMADA K, HOUKIN K, IWASAKI Y et al.: A high-field magnetic resonance imaging study of experimental vasogenic brain edema and its response to AVS: 1,2-bis (nicotinamido)-propane. Acta Neurochir. Wien (1994) 60 (Suppl.) .
   Google Scholar
• KOIDE T, ASANO T, MATSUSHITA H et al.: Enhancementof ATPase activity by a lipid peroxide of arachidonic acid in rat brain microvessels. j Neurochem. (1986) 46:235–242.
   PubMed Web of Science ®Google Scholar
• YOSHIMURA N, OKADA M, OTA T et al: Pharmacologicintervention for ischemic brain edema after retrograde cerebral perfusion. J. Thorac Cardiovasc. Surg. (1995) 109:1173–1181.
   PubMed Web of Science ®Google Scholar
• KOMIYA T, HIGURASHI K, IIZUKA K et al: A novel freeradical scavenger, nicaraven, inhibits human platelet aggregation in vitro. Clin. NeuropharmacoL (1999) 22:11–14.
   PubMed Web of Science ®Google Scholar
• ALAM MS, KU K, YAMAUCHI M et al.: Protective effects ofnicaraven, a new hydroxyl radical scavenger, on the endothelial dysfunction after exposure of pig coronary artery to hydroxyl radicals. Mol Cell Biochem. (1998) 178:237–243.
   PubMed Web of Science ®Google Scholar
• YAMANAKA K, KUMURA E, YOSHIMINE T et al.: Cellular expression of inducible nitric oxide synthase following rat cortical incision and its suppression by hydroxyl radical scavenger, 1,2-bis (nicotina-mido)propane. Neurosci. Res. (1998) 31:347–350.
   PubMed Web of Science ®Google Scholar
• ASANO T, JOHSHITA H, GOTOH 0 et al. The pathome-chanism underlying ischemic brain edema: the role of Na+, K+-ATPase of the brain microvessels. Neurol Surg. (1985) 13:1147–1159.
   Google Scholar
• MIZUKAMI M, NEICHI T, YAMAZAKI T et al. Effects of AVS (1,2-bis (nicotinamido) propane) on platelet function and vascular endothelium. Arzneimittelfor-schung (1984) 34:764–768.
   PubMed Web of Science ®Google Scholar
• GERMANO A, IMPERATORE C, D'AVELLA D, COSTA G, TOMASELLO F: Antivasospastic and brain-protective effects of hydroxyl radical scavenger (AVS) after experimental subarachnoid hemorrhage. J Neurosurg. (1998) 88:1075–1081.
   PubMed Web of Science ®Google Scholar
• ••An excellent experimental study of nicaraven in vasospasmdue to subarachnoid haemorrhage.
   Google Scholar
• ISHIGAI M, ISHITANI Y, ORIKASA Y et al.: Metabolism of 2 (R,S)-1,2-bis (nicotinamido)propane, a new agent with anti-vasospasm activity, in rats and rabbits. Arzneimittelforschung (1998) 48:429–435.
   PubMed Web of Science ®Google Scholar
• ASANO T, TAKAKURA K, SANO K et al.: Effects of a hydroxyl radical scavenger on delayed ischemic neurological deficits following aneurysmal subarach-noid hemorrhage: results of a multicenter, placebo-controlled double-blind trial. J Neurosurg. (1996) 84:792–803.
   PubMed Web of Science ®Google Scholar
• ••The only report of a Phase III trial of nicaraven in the Englishlanguage
   Google Scholar
• JAIN KK: Treatment of cerebral vasospasm. In: Neurobase. Arbor Publishing Corporation, San Diego, California, USA (2000b).
   Google Scholar
• ••Detailed description of various strategies used for themanagement of vasospasm. Electronic medium available to subscribers only.
   Google Scholar